Edit
Achaogen, Inc.
http://www.achaogen.com/Last activity: 17.07.2021
Probably Closed - Reference to Achaogen
Official HCP website for ZEMDRI®(plazomicin)—an antibiotic indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis.
Location: United States, California, City of San Francisco
Total raised: $87.6M
Investors 3
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | 5AM Ventur... | 5amventure... |
| 17.07.2021 | ARCH Ventu... | archventur... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.04.2010 | Series C | $56M | - |
| 09.01.2009 | - | $5.6M | - |
| 11.10.2006 | - | $26M | - |
Mentions in press and media 8
| Date | Title | Description |
| 21.05.2019 | New antibiotics are urgently needed, but economics stand in the way | Achaogen’s journey from promise to penury illustrates the Herculean task the biopharma industry faces: Fulfill a growing need for antibiotics while facing economic realities that make doing so unprofitable. As is apparent from the prolifera... |
| 21.05.2010 | Morning Read: Some good pharma news (finally) | Top VC recipients of 2010: As we (kind of) near the halfway point of 2010, peHUB runs down the top venture capital recipients so far. Alas, the healthcare industry has but one apperance and it’s at No. 10. Achaogen, a San Francisco-based de... |
| 07.04.2010 | ACHAOGEN COMPLETES $56 MILLION SERIES C FINANCING | - |
| 07.04.2010 | Achaogen Completes $56M Series C Financing | Achaogen, a South San Francisco, CA-based biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, completed a $5... |
| 09.01.2009 | Achaogen takes in $5.6M to fight bacterial infections | Pharmaceutical company Achaogen received a $5.6 million grant from the U.K.-based Wellcome Trust as part of its Seeding Drug Discovery Initiative. The money will go toward phase one clinical trials of the San Francisco company’s lead drug c... |
| 11.10.2006 | Achaogen, an antibacterial co., raises $26M | Achaogen, a South San Francisco developer of antibacterial compounds, said it has raised $26M in a second round of financing, led by new investor Domain Venture Partners. All of Achaogen’s first-round investors (5AM Ventures, ARCH Venture P... |
| - | Morning Read: Some good pharma news (finally) | Highlights of the important and the interesting from the world of healthcare: Finally! Some good pharma news: Amid what seems like an endless cascade of merger-inspired Big Pharma layoffs, one bright spot has emerged. Generic drugmaker Wats... |
| - | New antibiotics are urgently needed, but economics stand in the way | On March 10, 2017, shares of antibiotic developer Achaogen traded at $27 on the Nasdaq. Two years later, it has become a penny stock trading at around 9 cents per share after the company filed for bankruptcy under Chapter 11, on April 15, a... |